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Bone is the most common site for metastasis in cancer and is of particular clinical importance in breast and prostate cancers due to
the prevalence of these diseases. Bone metastases result in considerable morbidity and complex demands on health care resources,
affecting quality of life and independence over years rather than months. The bisphosphonates have been shown to reduce skeletal
morbidity in multiple myeloma as well as a wide range of solid tumours affecting bone by 30–50%. Quite appropriately, these agents
are increasingly used alongside anticancer treatments to prevent skeletal complications and relieve bone pain.
The use of bisphosphonates in early cancer is also increasingly important to prevent the adverse effects of cancer treatments on bone
health. These include ovarian suppression and the use of aromatase inhibitors in breast cancer patients and androgen deprivation
therapy in those with prostate cancer. Bisphosphonate strategies, similar to those used to treat postmenopausal osteoporosis, have
suggested that bisphosphonates are a safe and effective treatment for the prevention of treatment-induced bone loss.
When compared to other cancer therapies, the frequency and severity of adverse events related to bisphosphonate therapy are
generally mild and infrequent; thus, the benefits of treatment with any bisphosphonate almost always outweigh the risks. However,
renal dysfunction may occasionally occur and over recent years, a new entity, bisphosphonate-associated osteonecrosis of the jaw
(ONJ), has been described. The incidence, clinical importance and prevention strategies to minimise the impact of this problem on
patients requiring bisphosphonates is discussed.
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Bone is a common site for metastasis in patients with solid
tumours arising from the breast, prostate, lung, thyroid and kidney
(Brown et al, 2005). Approximately 70% of patients with advanced
prostate cancer or breast cancer and up to 40% of patients with
other advanced solid tumours will develop bone metastases.
Additionally, in more than 50% of men with advanced prostate
cancer and around 20% of women with advanced breast cancer,
metastatic disease appears clinically confined to the skeleton.
Bone metastases are typically referred to as osteoblastic,
osteolytic or mixed, based on the radiographic appearance of the
lesions. However, osteoblastic and osteolytic bone lesions repre-
sent two extremes of a spectrum and osteoclast activity is increased
in most bone metastases, including the typical osteoblastic
metastases from prostate cancer (Coleman, 2006). Pathological
activation of osteoclasts appears to play a central role in most
disease-related skeletal complications and is, thus, a rational
therapeutic target and the basis for the use of bisphosphonates
across the range of cancers affecting bone (Dunstan et al, 2007).
Metastatic bone disease disrupts the normal homeostasis of
bone, a dynamic process that involves the coupled and balanced
osteoclast-mediated osteolysis and osteogenesis by osteoblasts
(Coleman, 2006). The resulting increased and unbalanced bone
metabolism leads to a loss of bone integrity, which may result in
skeletal morbidity. This includes bone pain, pathological fractures,
a need for orthopaedic surgery to prevent or repair major
structural damage, spinal cord and nerve root compression and
hypercalcaemia of malignancy. Bone pain is the most prevalent of
all cancer-associated types of pain, and may be severe, necessita-
ting opiate analgesics and palliative radiation therapy and often
accompanied by a substantial decline in patient-reported quality of
life. Despite the many advances in the treatment of advanced
cancer over recent decades, skeletal morbidity remains a major
clinical problem with annual fracture rates of 20–40% and the
occurrence of a significant skeletal complication every 3–6 months
in the absence of bone-targeted therapies, such as bisphosphonates
(Brown et al, 2005).
In addition to the effects of spread of cancer to bone, there are
also important effects of cancer treatments on bone health. This is
largely mediated through endocrine effects of treatment, including
ovarian suppression, androgen deprivation therapy and the use of
aromatase inhibitors that block oestrogen synthesis in postmeno-
pausal women. With the improved survival that has emerged over
the past 30 years through improved diagnostic and therapeutic
interventions, the long-term effects of treatment on the skeleton
have become an important clinical problem and a specific rationale
for the use of bone-specific treatments (Lester et al, 2005).
Over the past two decades, the bisphosphonates have become
established as an important component of treatment in metastatic
disease and the management of osteoporosis. All bisphosphonates
are pyrophosphate analogues, characterized by a P-C-P containing
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central structure rather than the P-O-P of pyrophosphate, and a
variable side chain (Roelofs et al, 2006). The P-C-P backbone
renders bisphosphonates resistant to phosphatase activity and
promotes their binding to the mineralised bone matrix.
After intravenous administration of a bisphosphonate, approxi-
mately 50–75% of the injected dose binds avidly to exposed bone
mineral, where it is internalised by the osteoclast during bone
esorption and the remainder is excreted by the kidney. All
bisphosphonates suffer from poor bioavailability, when given by
mouth (o5%), and must be taken on an empty stomach, as they
bind to calcium in the diet. Once a bisphosphonate is taken up by
an osteoclast, it causes the disruption of a number of biochemical
processes involved in osteoclast function, typically resulting in
apoptosis of the cell.
The molecular mechanism of action is now established, with
nitrogen-containing bisphosphonates inhibiting farnesyl dipho-
sphatase and other enzymes of the mevalonate pathway (Roelofs
et al, 2006). Non-nitrogen-containing bisphosphonates, such as
clodronate, have a different mode of action and induce osteoclast
apoptosis through the generation of cytotoxic ATP analogues
(Roelofs et al, 2006). Recent studies also suggest that bispho-
sphonates have direct effects on tumour cells (Clezardin 2005)
and may enhance the antitumour activities of cytotoxic agents
(Neville-Webbe et al, 2005).
TREATMENT BENEFITS
Bisphosphonates to prevent skeletal morbidity and relief
of bone pain
Radiotherapy is the treatment of choice for localised bone pain
from metastasis, but the bisphosphonates provide an additional
treatment approach, especially for patients with poorly localised
bone pain or recurrence of bone pain in previously irradiated sites.
Approximately, one half of patients demonstrate significant
improvement in pain, an effect that appears to be independent
of the nature of the underlying tumour or radiographic appearance
of the metastases (Wong and Wiffen, 2002).
Additionally, based on the results of large randomised
controlled trials, conducted in the late 1990s, the bisphosphonates
have become the standard of care for the treatment and prevention
of skeletal complications associated with bone metastases in
patients with breast cancer and multiple myeloma (Coleman,
2004). More recently, as summarised in Table 1, they have also
demonstrated benefits in patients with bone metastases secondary
to other cancers, including prostate cancer (Saad et al, 2004), lung
cancer (Rosen et al, 2004) and a broad range of other solid
tumours (Rosen et al, 2004). This prophylactic use of bispho-
sphonates in managing bone metastases has had a profound
beneficial effect on the frequency and severity of skeletal
morbidity. With the use of modern potent agents, the proportion
of patients suffering from skeletal-related events (SREs) has been
reduced by 30–50% and this reduction has resulted in significant
and clinically important benefits in quality of life and preserved
function (Coleman, 2004).
Outside the United States, the choice of available agents for use
in oncology is considerable and includes both oral and intravenous
formulations of ibandronate and clodronate, and intravenous
zoledronic acid and pamidronate. The optimal type and route of
administration for a bisphosphonate to prevent skeletal morbidity
remains uncertain due to the lack of head-to-head comparisons
between the intravenous and oral agents. Zoledronic acid,
however, has proven effective across the range of solid tumours,
whereas the efficacy benefits of the other agents are restricted to
breast cancer and myeloma. Typically, in metastatic bone disease,
intravenous formulations are administered every 3 –4 weeks and
oral agents given on a daily basis. With the latter, strategy
compliance may be a significant problem (Cramer et al, 2007).
Cancer treatment-induced bone loss may also be an indication
for bisphosphonate use, especially if the subject has low bone
mineral density or risk factors for the occurrence of a low trauma
fracture (Lindsay et al, 1997). In this setting, the disturbance of
bone turnover is more similar to that seen in postmenopausal bone
loss and doses, and schedules of bisphosphonate treatment that are
similar to those used in osteoporosis are sufficient. Intravenous
zoledronic acid every 6 months (Gnant et al, 2007), monthly oral
Table 1 Effects of bisphosphonates on skeletal morbidity: results of randomized placebo-controlled trials
Agent and route N Results Investigator
Breast cancer
Clodronate 1600 mg po vs placebo 173 Reduced SMR– 305 vs 219 events/100 woman years (P¼o0.001) Paterson
Pamidronate 45 mg IV vs control 295 Increased time to bone progression–168 vs 249 days (P¼ 0.02) Conte
Delay in rst SRE–7.0 months vs 13.1 (P¼ 0.0005)
Pamidronate 90 mg IV vs placebo 382 Reduced proportion experiencing SRE–65% vs 46% (P¼o0.001) Hortobagyi
Pamidronate 60 mg IV vs control 401 Median time to skeletal progression –9 vs 14 months (P¼o0.01) Hultborn
Pamidronate 90 mg IV vs placebo 374 Reduced proportion experiencing SRE–67 vs 56% (P¼ 0.027) Theriault
Delay in rst SRE 6.9 months vs 10.4 (P¼ 0.049)
Ibandronate 2/6 mg IV vs placebo 467 Reduced SMR with 6 mg dose, 2 mg ineffective–SMR 2.18 vs 1.61 (P¼ 0.03) Body
Zoledronic acid 4 mg iv vs placebo 227 Reduced proportion experiencing SRE–50 vs 30% (P¼ 0.003) Kohno
Reduced SMR by 43% (P¼ 0.016)
Multiple myeloma
Clodronate 1600 mg po vs placebo 350 Improved 2-year progression-free survival –24 vs 12% (Po0.05) Lahtinen
Pamidronate 90 mg IV vs placebo 392 Reduced proportion experiencing SRE–24 vs 41% (Po0.001) Berenson
Clodronate 1600 mg po vs placebo 614 Less skeletal morbidity and pain on progression McCloskey
Prostate cancer
Clodronate (4 520) mg oral vs placebo 311 Reduction in number of SREs vs placebo not significant – (49 vs 41%, P¼NS) Dearnaley
Pamidronate 90 mg iv vs placebo 378 Number of SREs equal in pamidronate and placebo-arms, P¼ 1.0 Small
Zoledronic acid 4/8 mg vs placebo 643 25% reduction in proportion of patients experiencing at least one SRE– (P¼ 0.021) Saad
Other tumour types
Zoledronic acid 4/8 mg vs placebo 773 Significant delay to time of rst SRE (P¼ 0.023) Rosen
Reduction in proportion of patients with SRE– (47 vs 38%, P¼ 0.039)
SRE, skeletal-related event.
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ibandronate (Lester et al, 2007) and weekly oral risedronate (Van
Poznak et al, 2007) have all been shown to prevent bone loss
associated with the use of aromatase inhibitors for postmeno-
pausal breast cancer. In the context of androgen-deprivation
therapy, zoledronic acid every 3 –12 months is able to prevent
the bone loss associated with therapy (Smith et al, 2003;
Michaelson et al, 2007).
Treatment risks
When compared to other cancer therapies, the frequency and
severity of adverse events related to bisphosphonate therapy are
generally mild and infrequent; thus, the benefits of treatment with
any bisphosphonate almost always outweigh the risks. The side-
effect profile is mostly influenced by the administration route.
With intravenous amino-bisphosphonates, around 15–30% of
patients will experience an acute phase reaction probably related to
the stimulation of gdT cells and characterized by transient fever
and muscle and joint aches but this usually only follows the first
infusion and is largely irrelevant thereafter. Some data suggest that
the incidence of the acute phase response is less common in
immunocompromised advanced cancer patients than in healthy
subjects or in those without metastases.
Renal complications
Renal abnormalities have been described with intravenous agents,
particularly when they are given at high doses (above standard) or
as a rapid infusion. However, at the recommended dose and
schedule of any bisphosphonate, renal toxicity is unusual, usually
predictable and reversible, and serious bisphosphonate-induced
renal complications (including renal failure) are rare (o0.5%)
(Guarneri et al, 2005). Because renal dysfunction is infrequent,
none of the placebo-controlled trials with ibandronate or
zoledronic acid (when given at the currently recommended dose
and schedule) showed any statistically significant differences
between active therapy and placebo in creatinine levels with time.
However, idiosyncratic renal abnormalities undoubtedly do occur.
With pamidronate a focal glomerulosclerosis associated with
nephrotic syndrome is recognised, whereas with the use of
zoledronic acid, the renal abnormalities relate to tubular damage
(Guarneri et al, 2005).
There are suggestions that ibandronate is less likely than
zoledronic acid or pamidronate to influence renal function. This
has been attributed to the higher protein binding and prolonged
elimination half-life of ibandronate. There are undoubtedly more
case reports of renal dysfunction with zoledronic acid because the
drug is so widely used, but whether there truly is a renal safety
advantage to ibandronate remains uncertain. In the absence of
appropriately powered randomised comparative trials, it is not
possible to conclude on whether ibandronate truly has tolerability
advantages over the other agents.
Osteonecrosis of the jaw
In recent years, ONJ has become one of the most discussed adverse
events in advanced malignancy; partially stimulated by the
publication of photographs of extreme cases that often were
worsened by inappropriate surgery (Marx, 2003; Ruggiero, 2004).
In addition, these initial case series neither gave estimation of the
incidence of the problem nor indicated that most cases may be
managed conservatively using oral rinses and antibiotics.
Since the original reports of ONJ associated with the use of
bisphosphonates were produced 5 years ago, over 1000 other cases
have come to the attention of regulatory authorities around the
world and an ever-increasing number of case series, retrospective
cohort studies and insurance claim reviews have been published
(Ruggiero et al, 2006; Wilkinson et al, 2007). These studies have
not used a consistent definition for ONJ, although this has now
been defined as an area of exposed bone in the maxillofacial region
that did not heal within 8 weeks after identification by a health care
provider, in a patient who was receiving or had been exposed to a
bisphosphonate and had not had radiation therapy to the
craniofacial region (Khosla et al, 2007). Additionally, the methods
of data collection have varied; in some cases, they have used
inherently biased internet surveys or retrospective chart reviews.
The frequency of ONJ suggested by these exploratory reports has
varied considerably between o1 and 410% (Wilkinson et al,
2007). In the largest chart review from the MD Anderson Cancer
Centre, 4000 patients treated with bisphosphonates were reviewed
(Hoff et al, 2006). The overall incidence of ONJ, using a definition
of exposed bone for at least 3 months, was 0.83% with an
approximate time-dependent rate of 1% per year on treatment.
This could be an underestimate due to the inclusion of patients
who received only a single dose for hypercalcaemia. However,
these patients were treated before careful pretreatment, dental
assessment and avoidance of invasive dental procedures were
instituted, strategies that have almost certainly reduced the
frequency of ONJ (American Dental Association Council on
Scientific Affairs, 2006).
The pathogenesis of ONJ remains obscure. Local oversuppres-
sion of bone turnover in the jaw, and inhibition of angiogenesis by
high doses of potent amino-bisphosphonates complicating trauma
and infection of the jaw are the most likely contributing factors,
but a definite causal relationship between bisphosphonate use
and ONJ remains uncertain and complicated by factors that
may increase the risk of developing the condition, such as the
concomitant use of cancer treatments and/or corticosteroids,
requirements for dental surgery and comorbidities, such as
anaemia and diabetes (Hoff et al, 2006). Seventy-five percent
occur following a dental extraction or jaw surgery. Histopatho-
logically exposed necrotic bone, usually with an inflammatory
inflitrate and evidence of infection with a mixed bacterial growth
often containing actinomyces species, is observed.
Information on ONJ from randomised clinical trials is very
limited. A retrospective analysis of over 3000 patients included in
the zoledronic acid development programme identified a maxi-
mum of six patients who might, in hindsight, have experienced
ONJ, although some of these individuals may have had osteomyelitis
or other dental conditions (Novartis, 2005). In a recent
randomised trial of IV zoledronic acid, given to treat osteoporosis,
there were two possible cases of ONJ, one in the placebo arm and
one in the group receiving active treatment (Black et al, 2007).
Prospective research is required to determine the causes of ONJ
and the frequency of the condition using a consistent definition in
cancer patients treated with and without bisphosphonates. The
relationships, if any, with the type, dose and duration of
bisphosphonate treatment need to be defined, as do the strategies
for prevention, early diagnosis and subsequent treatment. In the
meantime, patients should have regular inspection of the mouth,
undergo dental checkups every 6– 12 months and avoid invasive
dental surgery unless no alternative is available (Hoff et al, 2006;
Wilkinson et al, 2007).
Optimising the risk/benefit ratio
Consensus guidance recommendations indicate that all patients
with multiple myeloma (American Society of Clinical Oncology,
2007) and radiologically confirmed bone metastases from breast
cancer (Hillner et al, 2003) should receive bisphosphonates from
the time of diagnosis of bone metastasis and continued
indefinitely.
The development of an SRE is not a specific sign of treatment
failure or a signal to stop treatment; evidence is now available to
confirm that bisphosphonates delay second and subsequent
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complications, not just the first event. However, a recent report
suggested that switching to a more potent agent (zoledronic acid)
may be an appropriate option in breast cancer patients in whom
pamidronate or clodronate therapy proves ‘unsatisfactory’
(Clemons et al, 2006).
Evidence-based criteria are needed to determine when in the
course of metastatic bone disease the bisphosphonates should be
started and stopped. Because of the logistics and cost of delivering
monthly intravenous infusions for all patients with metastatic bone
disease, empirical recommendations on who should receive
treatment that take into account the underlying disease type and
extent, the life expectancy of the patient, the probability of the
patient experiencing a SRE and the ease with which the patient can
attend for treatment (or be treated by a domiciliary service) appear
appropriate (Dunstan et al, 2007).
Despite the obvious clinical benets of bisphosphonates, only a
proportion of skeletal events are prevented. Additionally, some
patients do not experience a skeletal event despite the presence of
bone metastases. Bisphosphonates are a relatively costly additional
intervention in cancer care that is now potentially applicable to a
very large proportion of patients with advanced malignancy.
Although bisphosphonate use in some disease settings may be
associated with cost savings (Botteman et al, 2006), the cost
effectiveness of routine long-term treatment across all disease
types has been questioned (Reed et al, 2004; McKeage and Plosker,
2008), and this, coupled with the small but finite risk of toxicity,
suggests that a more selective use of bisphosphonates would be
appropriate.
Biochemical markers of bone metabolism provide valuable
prognostic information in patients with metastatic bone disease
and monitoring of bone resorption markers may be useful to
identify patients at high risk of skeletal complications and guide
the frequency of treatment (Brown et al, 2005; Coleman et al,
2005). In an analysis of patients with bone metastases from breast
cancer, prostate cancer, lung cancer or other solid tumours, or
bone lesions from multiple myeloma that elevated on treatment
levels of N-telopeptide of type 1 collagen (NTX) were associated
with a significant 2-fold increased risk of disease progression and
risk of skeletal complications (P o0.001 for all). In addition,
elevated NTX levels were associated with a significant two- to
threefold increased risk of experiencing a first SRE on study in
patients with breast cancer, prostate cancer or multiple myeloma
(Pp0.008). Furthermore, elevated NTX levels were associated with
a significant four- to sixfold increased risk of dying on study in all
solid tumour patients (Po0.001 for all) (Coleman et al, 2005).
A more cost-effective use of bisphosphonates, particularly in
patients with additional extensive visceral metastases or solid
tumours associated with a short-life expectancy, might be to
reserve them until patients have raised NTX levels and to adjust
the frequency of treatment to maintain levels of bone resorption
within the normal range, increasing the interval between
treatments when the disease is in remission and the rate of bone
resorption is normal. Bone-marker-directed therapy is under
evaluation in randomised clinical trials and the value of
maintenance therapy after 1 to 2 years of treatment may become
clear from the ongoing Optimize trial in the United States.
Conclusion
The use of bisphosphonates in oncology has had a profound
beneficial effect on the management of metastatic bone disease and
the prevention of treatment-induced bone loss. Their use should
be considered in all patients with bone metastases, especially those
with symptoms and without immediately life-threatening extra-
skeletal disease. Guidelines for the use of the agents in preventing
treatment-induced bone loss are evolving and trials investigating
their potential role in the adjuvant setting to prevent metastasis are
ongoing (Table 2). As a class, the agents are well tolerated.
Occasional serious toxicities in terms of renal impairment and ONJ
can be largely avoided through adhering to the recommended dose
and infusion times and good preventative dental care, respectively.
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